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Rodrigues P H A shareholders 4 . Such corporate characteristics will be present in all cases of PPPs, leading one to wonder whether any of these partnerships can be classified as "possible", as proposed by Costa e Silva et al.
As for the fourth issue I raise in the debate, there is a sophisticated ideological construction concerning the role of the 'capitalist entrepreneur', and thus of corporations as the principal vector of innovation, as proposed by Schumpeter 5 . The Schumpeterian view attributes to the private sector almost a mythical leadership role in scientific and technological development, constituting the principal justification for patents and for the emphasis by large pharmaceutical laboratories on orphan drugs for rare diseases, in contrast with their disinterest in neglected diseases, two obvious examples of conflict with public health. Such a view omits and distorts the national states' role in innovation, science, and technology and is incapable of explaining how innovation has occurred or can occur in non-capitalist societies, for example.
The findings by Mazzucato 6 , based on a comprehensive investigation commissioned by the British government, contradict entirely the Schumpeterian construct, the pillar of the market ideology on innovation. Her results show that national states have been the principal vector for scientific research in all the main fields of knowledge. An important reason for this is that private investors' 'risk aversion' alienates them from financing basic research, which generally involves a large dose of "Knightian uncertainty" -a risk that "cannot be measured", that cannot be calculated -due to the long timeframes and the need to invest in projects that sometimes fail to prove their hypotheses or that involve random or uncertain development. For these reasons, the national state has played the leading role in financing and executing basic research -through a wide network of public research institutions. Companies concentrate on applied research, starting from basic research that has produced promising results. Applied research entails less risk and higher odds of obtaining profits.
The issues raised above do not contradict the article's central idea on the need for a risk classification system for PPPs, but they do express a bit more skepticism towards the potential advantages of such partnerships and suggest a certain dose of caution towards the proposed scale. In conclusion, I raise an issue concerning the very nature of PPPs: if what prevails in market societies is conflict rather than cooperation between the principles of economic liberalism and society's self-defense, isn't the very term "partnership" somewhat elusive, loaded with ideological connotations that can induce one to errors of evaluation? When we think of risk mediation systems, it is never too much to recall the tragic error of the prestigious risk classification agencies in the financial crisis of 2008-2009. 
